Company
Company
No. 63518 of 104260top 61%
1 direct links
In a group of 5 closely linked entities, around
New links this week
Weighted by public relations with evidence, recomputed daily.
Who invests in, owns, acquires or finances whom, from the relations AiSeek holds with evidence.
Lines show that a relation exists and which way it points; their thickness carries no amount. Dots only move to show the direction.
Arrows show the direction of the relationship. Filter to focus on a business area.
PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…View source
Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.View source
Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical companyView source
Showing 1 to 3 of 3
Read the assertion alongside its sources. Expand a row to inspect the evidence.
Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical company
PR Newswire news releases · 2026-11-13 02:00
Nexus Pharmaceuticals is a U.S. based specialty pharmaceutical companyView source
PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…
PR Newswire news releases · 2026-11-13 02:00
PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…View source
Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.
PR Newswire news releases · 2026-11-13 02:00
Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies.View source
Showing 1 to 3 of 3
Valuation data is available on Pro and Research.
Included in ProKnow a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.
Not available: Company signals · Financials · Filings · Sites · Guidance